Impax Laboratories (IPXL) Misses Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. S
10. COF

Go back to Impax Laboratories (IPXL) Misses Q2 EPS by 1c

Leerink Partners Cuts Price Target on Impax Laboratories (IPXL) Following 2Q15

August 11, 2015 9:05 AM EDT

Leerink Partners maintained a Market Perform rating on Impax Laboratories (NASDAQ: IPXL), and cut the price target to $47.00 (from $49.00), following its 2Q15 earnings report. IPXL reported revenue of $214m compared to the Street's $200m estimate. IPXL lowered its 2015 GM guidance, now in the low 50s (vs.... More

Impax Laboratories (IPXL) Sells Daraprim U.S. Rights in $55M Deal

August 10, 2015 6:31 AM EDT

Impax Laboratories (NASDAQ: IPXL) announced that it has sold its U.S. rights to the Daraprim brand to Turing Pharmaceuticals AG for approximately $55 million.

Impax acquired Daraprim as part of the Company's acquisition of Tower Holdings, Inc. (including operating subsidiaries CorePharma LLC and Amedra... More